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Identification of the PDI-Family Member ERp90 as an
Interaction Partner of ERFAD
Jan Riemer¤a, Henning G. Hansen, Christian Appenzeller-Herzog¤b, Linda Johansson, Lars Ellgaard*
Department of Biology, University of Copenhagen, Copenhagen, Denmark
Abstract
In the endoplasmic reticulum (ER), members of the protein disulfide isomerase (PDI) family perform critical functions during
protein maturation. Herein, we identify the previously uncharacterized PDI-family member ERp90. In cultured human cells,
we find ERp90 to be a soluble ER-luminal glycoprotein that comprises five potential thioredoxin (Trx)-like domains. Mature
ERp90 contains 10 cysteine residues, of which at least some form intramolecular disulfides. While none of the Trx domains
contain a canonical Cys-Xaa-Xaa-Cys active-site motif, other conserved cysteines could endow the protein with redox
activity. Importantly, we show that ERp90 co-immunoprecipitates with ERFAD, a flavoprotein involved in ER-associated
degradation (ERAD), through what is most likely a direct interaction. We propose that the function of ERp90 is related to
substrate recruitment or delivery to the ERAD retrotranslocation machinery by ERFAD.
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Introduction
In the endoplasmic reticulum (ER), critical protein maturation
steps including N-glycosylation and disulfide-bond formation take
place. Upon folding, native proteins can exit the ER by the
secretory pathway, whereas misfolded proteins and incompletely
assembled protein complexes are generally retained by a protein
quality control machinery [1]. Terminally misfolded proteins are
degraded by the ER-associated degradation (ERAD) pathway,
which involves the retrotranslocation of protein substrates to the
cytosol and proteasomal degradation [2–5]. To alleviate unfolding,
ERAD substrates that contain disulfide bonds might also have to
be reduced before retrotranslocation [6,7]. Recently, ERdj5, a
member of the protein disulfide isomerase (PDI) family, has been
demonstrated to facilitate this reduction step for certain ERAD
substrates [8]. The electron donor for ERdj5 remains to be
identified, and neither is it clear whether ERdj5 is the only
reducing PDI-family member involved in ERAD.
The PDI family encompasses around twenty members in
mammalian cells [9,10]. These proteins perform functions in
oxidative folding, protein retention, as chaperones and in ERAD.
All PDI-family members contain one or more domains with a
thioredoxin (Trx) fold. This fold typically consists of an N-terminal
bab motif, a connecting loop containing one a-helix, and a C-
terminal bba motif. The b-strands form a central b-sheet that is
surrounded by the a-helices. Redox-active PDI-family members
contain one or more so-called a type Trx-like domains with an
active site CXXC motif (C: Cys, X: any amino acid) that localizes
to the N-terminus of the second a-helix [11]. The non-catalytic b
type Trx-like domains lack the active-site cysteines, but instead
provide important functionalities in substrate binding and/or
chaperone activity [12–14].
We recently identified the ER-luminal flavoprotein ERFAD
(ER flavoprotein associated with degradation; also known as
FOXRED2) that participates in ERAD steps before retrotranslo-
cation from the ER, although the precise mechanism of action
remains unresolved [15]. ERFAD has also been shown to be
upregulated by amyloid b in rat cortical neurons and SH-SY5Y
cells [16]. This upregulation correlated with amyloid b neurotox-
icity, the inhibition of proteasome activity and induced ER stress-
mediated cell death [16]. ERFAD comprises consensus motifs for
binding of the two redox cofactors flavin adenine dinucleotide and
nicotinamide adenine dinucleotide phosphate. When purified from
human cells the protein binds flavin adenine dinucleotide, and we
have proposed a potential redox-function of the protein in ERAD
[15]. In cells, ERFAD interacts with the ERAD factors OS-9,
ERdj5, and SEL1L [15]. Here, we identify and characterize the
previously unknown PDI-family member ERp90 as a further
interaction partner of ERFAD.
Results
Co-immunoprecipitation with ERFAD identifies ERp90
We recently found ERFAD to interact with a number of well-
known ERAD components and several other proteins in a
complex that could be stabilized by crosslinking [15]. To further
characterize this protein complex we sought to identify additional
components. To this end, we used a HEK293-derived cell line
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stably expressing ERFAD with an HA tag inserted immediately
prior to the C-terminal KEEL sequence (A11 cells, [15]). From a
[35S]-methionine-labeled extract of these cells we immunoprecip-
itated ERFAD-HA (Figure 1A). The experiment revealed one
clear candidate interacting protein that was not recovered from
control cell lysates. This protein had an apparent size of ,90 kDa
and contained endoglycosidase H (EndoH)-sensitive glycans
indicating localization in the early secretory pathway (Figure 1B).
The interaction was not dependent on the formation of
intermolecular disulfide bonds since the protein could be
precipitated under reducing conditions (Figure 1A, lane 3). A
similar result was obtained after pretreatment with the oxidant
diamide (Figure 1A, lane 4). Upscaling of the co-immunoprecip-
itation (co-IP) experiment allowed protein identification using an
EndoH-treated sample (Figure 1B). After excision of the protein
band from a sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) gel and trypsin digestion, mass spectrometry
identified two proteins: SEL1L (as previously published [15]) and a
hitherto uncharacterized protein (RefSeq: NP_065835; gene
name: KIAA1344) (Figure S1). Based on its mobility by SDS-
PAGE and its ER localization (see below), we named this protein
ERp90. Since we identified both SEL1L and ERp90 from the
same band of the EndoH-treated sample, a more detailed analysis
necessitated the use of an ERp90 antibody. Thus, we raised an
antibody against a single purified domain of ERp90 (Trx3; see
below) expressed in E. coli. After affinity purification, this
antiserum recognized the antigen (data not shown), but did not
detect a band corresponding to endogenous ERp90 by Western
blot analysis of cell lysates. However, we were able to re-
precipitate endogenous ERp90 from lysates of radioactively
labeled A11 cells following IP of ERFAD-HA (Fig. 1C, lane 4).
Using this approach, and comparing to the migration of SEL1L,
we could demonstrate that the glycosylated 90 kDa band
coprecipitating with ERFAD-HA was ERp90 (Fig. 1C).
ERp90 is a member of the PDI family
The human ERp90 cDNA encodes a protein of 825 amino
acids (Figure 2A and 2C). The N-terminal 27 residues are
predicted to constitute an ER signal sequence, whereas no obvious
ER retrieval motif is present at the C-terminus (see below). The
mature ERp90 protein has a calculated molecular mass of
90.5 kDa. By secondary structure prediction we identified five
potential Trx-like domains (Trx1-5) in ERp90 (Figure 2B). Such
domains are a hallmark of proteins of the PDI family [11].
However, none of the five Trx domains in ERp90 contain the
typical active-site CXXC motif of redox-active Trx-like domains.
Figure 1. Identification of ERp90 as novel protein interacting with ERFAD-HA. (A) Immunoprecipitation of ERFAD-HA. Cells stably
expressing ERFAD-HA (A11) and control cells (FRT) not overexpressing the protein were [35S] pulse-labeled for 16 hours, treated as indicated, Triton
X-100 lysates immunoprecipitated with anti-HA, and samples separated by reducing SDS-PAGE. CHO, N-glycans. The arrowhead indicates the novel
protein that was coimmunoprecipitated with ERFAD-HA. (B) The approach from (A) was upscaled and analysed by mass spectrometry. The positions
of ERFAD-HA as well as of the identified protein – ERp90 – are indicated. (C) Immunoprecipitations on lysates of A11 cells that were [35S] pulse-
labeled to steady state were performed with anti-HA. The immunoprecipitate was either analyzed directly (lane 1) or reimmunoprecipitated using
HA- (lane 2), SEL1L- (lane 3) or ERp90- (lane 4) antibodies. The positions of the individual proteins are indicated and the glycosylated 90 kDa band
coprecipitating with ERFAD-HA can thereby be attributed to ERp90. The hairline indicates that one lane has been removed.
doi:10.1371/journal.pone.0017037.g001
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BLAST searching revealed the PDI-family member ERp57 as the
closest homologue of ERp90. Specifically, similarity is observed
between the Trx3-5 domains of ERp90 and the abb’ domains of
ERp57, with the ERp90 Trx3 and ERp57a domains showing the
highest sequence similarity (Figure S2). It is noteworthy that the
regular secondary structure elements determined experimentally
in ERp57abb’ show a high degree of conservation with those
predicted in the corresponding region of ERp90 (Figure S2),
supporting the assignment of the ERp90 Trx3-5 domains.
Database searching revealed orthologs of ERp90 in a number of
vertebrates, urochordates and in S. purpuratus (a sea urchin), but not
in the model organisms S. cerevisiae, D. melanogaster and C. elegans. An
alignment of different ERp90 orthologs revealed high conservation
over almost the complete ERp90 sequence (Figure S3). For
instance, the sequence identity between the human (residues 42-
819) and Xenopus tropicalis sequences was 48%.
Human ERp90 contains a total of 10 cysteine residues in the
mature protein and four predicted N-glycosylation sites
(Figure 2C). Three of the five predicted Trx-like domains contain
short conserved di-cysteine motifs (Trx1: CX8C, Trx2: CX9C,
Trx3: CX6C; Figure 2C and S3). In Trx1 and Trx3 these motifs
are located in equivalent positions with the first cysteine placed in
the loop following b3 and the second positioned in a3. Several PDI
proteins contain similar motifs in this position, e.g. ERp57a
(Figure S2) where the two cysteines form a structural disulfide. The
CX9C motif in Trx2 localizes in a different position to a predicted
loop region further C-terminal in the sequence (see Fig. 2C). In
addition, a seventh cysteine in position 664 (Trx5) is conserved in
almost all orthologs (Figure S3). It is noteworthy that one of the
four consensus sites for N-glycosylation in the human ERp90
sequence is also conserved in a high number of orthologs (N460
located in the predicted loop between a3 and b4 in Trx3),
indicating an important structural and/or functional role.
The human ERp90 protein contains a C-terminal
extension compared to its orthologs
The ERp90 gene is located on chromosome 14q22.1, and is
predicted to cover 121.91 kb of genomic DNA and contain 21
exons. The transcript length is predicted to 4.56 kb excluding the
polyA tail (Figure 3A). We confirmed this prediction by Northern
blot analysis using probes directed against the ERp90 mRNA
(Figure 3B). Here, we detected one clear band that migrated at
approximately 5 kb. Subsequent in silico (not shown) and RT-PCR
analyses showed a broad tissue and cell line distribution of human
ERp90 transcripts (Figure 3C).
Curiously, the human ERp90 protein is predicted to contain an
additional six amino acids at the C terminus compared to all other
orthologs (Figure S3). Moreover, the C-terminal four residues of
the orthologs display similarity to a canonical KDEL ER-retrieval
sequence (Figure S3). To determine the sequence of the ERp90 C-
terminus we first isolated total mRNA from both HEK293 and
HT1080 cells, and performed reverse transcription. We then
amplified a region of the ERp90 cDNA that covers the 39 end of
the ERp90 open reading frame and the beginning of the 39
untranslated region. Subsequent sequencing of the PCR products
revealed that the human ERp90 gene in both cell lines indeed does
encode for a C-terminally extended form of the protein (data not
shown).
Figure 2. ERp90 contains five predicted Trx domains. (A) Domain organization of the human ERp90 protein based on sequence analysis. The
positions of the five predicted Trx-like domains (Trx1-5) are depicted. (B) Secondary structure predictions for Trx1-5 in comparison to a Trx consensus
domain. The secondary structure elements were predicted with PSIPRED [26], APSSP2 [27], and PROFseq [28]. The resulting sequence borders of the
individual domains are given in the parentheses. (C) The amino acid sequence of ERp90 with the five Trx domains color-coded as in (A). Above the
sequence, the location of predicted secondary structure elements are shown (cylinders indicate a-helices, and arrows b-strands). The N-terminal helix
is part of the signal sequence. Cysteines are colored yellow, and the asterisks (*) mark four consensus sites for N-glycosylation.
doi:10.1371/journal.pone.0017037.g002
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Identification of a disulfide bond in recombinant ERp90
Trx3
For biochemical studies on ERp90 we first expressed the full-
length protein in E.coli. However, we only succeeded in purifying
small amounts of ERp90 extracted from inclusion bodies under
denaturing conditions. We therefore decided to purify a single
thioredoxin-like domain of ERp90. Due to the relatively high
sequence similarity with ERp57a (Figure S2), we chose to work
with ERp90 Trx3. Using this domain, we tested whether the
cysteines in the CX6C motif form a disulfide bond. Here, we
employed a gel shift assay based on alkylation with the maleimide
reagent 4-acetamido-49-maleimidylstilbene-2,29-disulfonic acid
(AMS) (Figure 4B). AMS efficiently reacts with free, but not with
oxidized cysteines. In our experience, for proteins up to around
50 kDa modification of even just two cysteines with AMS
(molecular weight: 499 Da) can add sufficient additional mass to
introduce a detectable mobility shift by SDS-PAGE (see e.g. [17]).
While the untreated ERp90 Trx3 domain did not shift upon AMS
incubation, we observed full modification when ERp90 Trx3 was
incubated with the reductant dithiothreitol (DTT) at 95uC under
denaturing conditions prior to AMS treatment (Figure 4B,
compare lanes 2 and 3). When incubating ERp90 Trx3 with
DTT at 25uC under native conditions only a minor fraction of the
Trx3 molecules became accessible for modification with AMS
(Figure 4B, lane 4). These data indicate that the two cysteines of
the CX6C motif in ERp90 Trx3 form a structural disulfide bond,
as is the case for the cysteines of this motif in ERp57a [18–20], the
a-domain of yeast PDI (Pdi1pa) [21,22] and in all six Trx-like
domains of ERdj5 [23].
ERp90 is a soluble glycoprotein of the ER
To analyze endogenous ERp90 in cells, we used our ERp90
antiserum in a double IP approach (see Material and Methods).
Thereby, we were able to precipitate endogenous ERp90 as well as
overexpressed myc-ERp90 from lysates of radioactively labeled
cells (Figure 5A and S4, respectively). As expected for an ER
Figure 3. Transcriptional analysis of ERp90. (A) Exon-intron structure of the human ERp90 gene. Vertical lines indicate positions of the 21
predicted exons. (B) Northern blot detection of the ERp90 mRNA in human tissue-culture cells. A nitrocellulose membrane with RNA from three
different human tissue-culture cell lines was hybridized with a radioactively labeled ERp90 cDNA probe (top). The rRNA signals served as loading
controls (bottom). (C) RT-PCR analysis of ERp90. Total RNA was isolated from various human tissue-culture cells, reverse transcribed and amplified
with primers specific for ERp90 and actin. HeLa: cervical epithelial carcinoma; Huh7, HepG2: hepatocellular carcinoma; CF-PAC-1: pancreatic adeno
carcinoma; A375, Meljuso: melanoma; HT1080: fibrosarcoma breast cancer; OVCAR3, SKOV3: ovarian epithelial carcinoma; LRB003, LRB010: embryonic
stem cells.
doi:10.1371/journal.pone.0017037.g003
Figure 4. Purification and characterization of recombinant ERp90 Trx3. (A) Coomassie-stained gel of purified ERp90 Trx3. Lane 1, molecular
weight marker; lane 2, purified ERp90 Trx3. (B) AMS shift assay performed on purified ERp90 Trx3. After treatment as detailed above the gel, the
protein was TCA precipitated and resuspended in a denaturing buffer containing AMS (except for the control, lane 1). Note that DTT treatment was
performed for 5 min at either 95uC (lane 3) or room temperature (lane 4). The samples were then subjected to SDS-PAGE and proteins were visualized
by Coomassie-staining. The positions of oxidized (OX) and reduced (RED) ERp90 Trx3 in this assay are indicated. The hairline indicates where a lane
has been removed from the gel.
doi:10.1371/journal.pone.0017037.g004
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protein with four potential N-glycosylation sites, the band
representing endogenous ERp90 showed increased mobility upon
EndoH cleavage (Figure 5A). Due to the rather low quality of the
ERp90 antiserum we used transient expression of myc-tagged
ERp90 in HEK293 cells for further experiments. The myc-ERp90
used was the full-length human protein including the C-terminal
extension that we verified by RT-PCR (see above and Figure S3).
In accordance with the results for endogenous ERp90 we found
that myc-ERp90 migrated at ,95 kDa (Figure 5B). Myc-ERp90
displayed EndoH sensitivity and, upon DTT treatment, decreased
gel mobility was observed (Figure 5B). Thus, at least some of the
10 cysteines in mature ERp90 were engaged in intramolecular
disulfide bonds. To confirm the presence of disulfide bonds in
ERp90 we used an alternative approach that has previously been
applied to visualize the CX6C disulfide bond in ERp57a [17]. We
first blocked free cysteines in situ using the alkylating agent N-ethyl
maleimide (NEM). After cell lysis, we then reduced disulfide-
bonded cysteines and modified them with AMS. By this
procedure, only cysteines that were oxidized in the cell become
modified with AMS. This approach confirmed that some of the
cysteines in ERp90 are engaged in disulfide bonds (Figure 5C), in
agreement with the in vitro analysis of Trx3 (Fig. 4B) that was
performed under comparable experimental conditions (i.e. SDS
denaturation at high temperature, reduction and then modifica-
tion with AMS).
Next, we used alkali extraction of crude membranes isolated
from HEK293 cells expressing myc-ERp90 to investigate whether
the protein was soluble or membrane-bound. The membranes
were extracted using sodium carbonate at pH 11.3, and the
soluble and insoluble fractions were separated by ultracentrifuga-
tion before analyzing the presence of myc-ERp90 in either fraction
by Western blotting. We found all myc-ERp90 in the same
fraction as ERp57 (the control for soluble proteins), but not in the
fraction containing the membrane protein TMX3 (Figure 5D),
clearly indicating ERp90 to be a soluble protein.
The EndoH sensitivity of ERp90 already indicated a localiza-
tion of the protein to the secretory pathway. However, due to the
absence of an ER-retrieval signal it remained unclear whether
ERp90 indeed was an ER-resident protein. Using immunofluo-
rescence microscopy we observed a reticular staining pattern for
transiently expressed myc-ERp90 and co-localization with an ER-
targeted variant of the green fluorescent protein (GFP-KDEL)
(Figure 5E). At the same time, a small fraction of myc-ERp90 was
detected in the culture medium (data not shown). However, we
consider the latter finding to be a likely result of overexpression,
which could well saturate the retention mechanism for ERp90.
Figure 5. ERp90 is a soluble ER-glycoprotein. (A) Glycosylation state of ERp90. Lysates of pulse-labeled HEK293 cells were subjected to IP and
re-IP with anti-ERp90. CHO, N-glycans. (B) Glycosylation and oxidation state of myc-ERp90. HEK293 cells transiently overexpressing myc-ERp90 were
lysed after preincubation with the cell-permeable alkylating agent NEM to block free cysteines. The lysate was treated as indicated and extracts were
analyzed by anti-myc Western blotting. CHO, N-glycans. (C) Oxidation state of myc-ERp90. HEK293 cells transiently overexpressing myc-ERp90 were
lysed after preincubation with the cell-permeable alkylating agent NEM to block free cysteines. The lysate was treated with the reductant TCEP. Then,
originally oxidized cysteines were modified with AMS. The resulting samples were analyzed by Western blotting with anti-myc. (D) Subcellular
fractionation of HEK293 cells transiently expressing myc-ERp90. Crude membranes were isolated and extracted with sodium carbonate. The soluble
and insoluble fractions were separated by ultracentrifugation through a sucrose cushion. The distribution of myc-ERp90, ERp57 (a soluble ER protein)
and TMX3 (an ER membrane protein) was visualized by Western blotting. Asterisk, background band. (E) Confocal immunofluorescence microscopy of
HEK293 cells transiently expressing myc-ERp90. HEK293 cells transiently co-expressing myc-ERp90 (red) and GFP-KDEL (green) were fixed, and stained
with anti-myc. A merged image is shown in the right panel.
doi:10.1371/journal.pone.0017037.g005
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Overall, the data show that ERp90 is a soluble, disulfide-
containing glycoprotein of the ER.
ERp90 forms a stable interaction with ERFAD
Next, we wanted to characterize the interaction between
ERFAD and ERp90 in more detail. We first immunoprecipitated
ERFAD-HA from A11 cells using anti-HA, and then analyzed the
precipitate by Western blotting with anti-ERp90 (Figure 6A). We
also immunoprecipitated myc-tagged ERp90 overexpressed in
HEK293 cells with anti-myc, and analyzed the eluted proteins by
Western blotting with anti-ERFAD (Figure 6B). The results clearly
showed that ERFAD-HA specifically co-precipitated endogenous
ERp90 (Figure 6A, compare lanes 2 and 4) and myc-ERp90 co-
precipitated endogenous ERFAD (Figure 6B, compare lanes 2 and
4). Importantly, IP of ERFAD from [35S]-methionine-labeled
HEK293 cell lysates followed by re-IP against ERp90 confirmed
the interaction between the two endogenous proteins (Figure 6C,
lane 4). To obtain an indication of whether ERp90 and ERFAD
interact directly, we tested if we could purify the complex of
ERp90 and ERFAD from metabolically labeled cells that
expressed tagged versions of both proteins (3B2B-myc-ERp90
cells expressing ERFAD-FLAG and myc-ERp90) (Figure 6D).
First, we immunoprecipitated ERFAD-FLAG under native
conditions taking care to elute the precipitated proteins under
mild conditions using the FLAG peptide. We then performed a
second native IP against the myc tag of ERp90. When we analyzed
this latter precipitate we found that the predominant species
purified were ERFAD-HA and myc-ERp90 (Figure 6D, lane 3)
suggesting a stable and direct interaction between ERFAD and
ERp90.
Discussion
In this study we identify ERp90 as a new member of the PDI
family and an interaction partner of the ERAD component
ERFAD. Moreover, our preliminary data indicate that, like
ERFAD [15], ERp90 can be crosslinked to a larger complex of
proteins. At least certain of the bands in the two complexes
immunoisolated with antibodies against ERFAD and ERp90,
respectively, migrate at the same apparent molecular mass (data
not shown). Based on these finding we cannot rule out entirely that
ERFAD and ERp90 interact indirectly through other components
of this complex. However, since the interaction between the two
proteins withstands re-IP and because other proteins were much
less abundant in the precipitate, we currently favor the idea that
the interaction is direct.
The interaction between ERp90 and ERFAD strongly implies a
functional link. This notion is reinforced by the presence of the two
proteins in the same set of organisms. Since we did not succeed in
performing siRNA-mediated knockdown experiments of ERp90 to
Figure 6. Analysis of the ERp90–ERFAD interaction. (A) ERp90 co-immunoprecipitates with ERFAD-HA. IPs from A11 or HEK293 cell lysates
were performed with anti-HA, and analyzed by Western blotting with antibodies against ERp90 and the HA tag. 0.2% of the total lysate were directly
analyzed as input. Asterisk, background band. (B) ERFAD co-immunoprecipitates with myc-ERp90. Anti-myc immunoprecipitates from lysates of
HEK293 cells transiently overexpressing myc-ERp90 or an empty vector (mock) were subjected to Western blotting using the indicated antibodies.
Asterisk, background band. (C) Endogenous ERFAD co-immunoprecipitates endogenous ERp90. ERFAD was immunoprecipitated from [35S] pulse-
labeled HEK293 cells using a pre-immune serum or an ERFAD antiserum. The immunoprecipitate was either analyzed directly (lanes 1 and 2; one
tenth of first immunoprecipitate loaded) or re-immunoprecipitated with antibodies against ERFAD (lane 3) or ERp90 (lane 4; three times the amount
compared to the ERFAD re-immunoprecipitation in lane 3). The hairline indicates where a lane has been removed from the autoradiograph. (D)
Overexpressed ERFAD-His-FLAG and myc-ERp90 can be co-purified. 3B2B-myc-ERp90 cells were [35S] pulse-labeled overnight and subjected to anti-
FLAG IP. ERFAD-His-FLAG and its interacting partners were eluted with the FLAG peptide under native conditions (lanes 1 and 2), and subsequently
re-immunoprecipitated with anti-myc under native conditions (lane 3).
doi:10.1371/journal.pone.0017037.g006
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study an involvement of ERp90 in ERAD, we can presently only
speculate about the function of ERp90 in relation to ERFAD.
While ERFAD likely catalyzes a redox reaction, ERp90 could
recruit misfolded proteins to the complex by virtue of its redox-
inactive thioredoxin-like domains. Substrates bound by the
complex of ERFAD and ERp90 could then be delivered and
handed over to SEL1L, a function resembling the one recently
described for OS-9 and GRP94 [24]. Alternatively, ERFAD and
ERp90 could work on substrates already bound by SEL1L or OS-
9, and potentially also assist the transfer of substrates from either of
these proteins to a retrotranslocation channel. Finally, ERp90
could perform a CXXC-independent redox function, conceivably
in collaboration with the redox-active ERFAD, through the
conserved C664 or even the CX9C motif in the Trx2. Future work
should allow us to distinguish between these various possibilities.
Materials and Methods
Primers and plasmids
The ERp90 full-length cDNA clone fj00476s1 (KIAA1344) was
obtained from the Kazusa DNA Research Institute, and the
pCMV/myc/ER/GFP, pcDNA3, pcDNA5-FRT and pOG44
plasmids were from Invitrogen. The pFH255 plasmid was a gift
from Dr. Lloyd Ruddock, University of Oulu. The following
plasmids were constructed as described in Text S1: pcDNA5FRT/
myc-ERp90, pcDNA3.hygro/myc-ERp90, and pMAL-c2X/
MBP-Xa-ERp90Trx3.
Antibodies
The following antibodies were used: anti-HA (16B12, Covance),
anti-myc (9E10, Covance), anti-ERp57 (gift from A. Helenius,
ETH Zurich, Switzerland), anti-TMX3 [25], anti-ERFAD [15]
and anti-SEL1L (gift from H. Ploegh, Whitehead Institute,
Cambridge, MA, USA). The secondary anti-rabbit and anti-
mouse IgGs coupled to horseradish peroxidase were obtained from
Pierce, and the Alexa Fluor 594 anti-mouse IgG from Invitrogen.
A polyclonal serum against ERp90 (anti-ERp90) was generated by
immunizing rabbits with the Trx3 domain of ERp90 purified from
E. coli (see below). The obtained antiserum (56E) was affinity
purified as follows: After SDS-PAGE, purified ERp90 Trx3 was
blotted onto a nitrocellulose membrane. The membrane was
stained with ponceau red and the region containing ERp90 Trx3
was cut out. The obtained nitrocellulose ‘‘strips’’ were blocked and
then incubated with the anti-ERp90 serum overnight at 4uC.
Strips were then washed, transferred to low salt buffer (10 mM
Tris/HCl pH 7.5; 10 mM NaCl), and the antibodies eluted with a
low pH buffer (100 mM glycine/HCl pH 2.8). The eluted
antibody was immediately neutralized with 5 M NaOH and
1 M Tris, dialyzed overnight into PBS, concentrated, and
supplemented with glycerol (to 50%).
Cell lines
The generation of cell lines overexpressing ERFAD-HA (A11)
and ERFAD-His-FLAG (3B2B) has been described [15]. The cell
line stably expressing myc-ERp90 was generated using the Flp-In
TREX system from Invitrogen (myc-ERp90 in HEK293-TREX,
selected with 0.1 mg/ml hygromycin B and 15 mg/ml blasticidin).
The 3B2B-myc-ERp90 cell line was generated by transfecting
3B2B cells with pcDNA3.hygro/myc-ERp90 and selecting with
0.1 mg/ml hygromycin B. All cells were cultured in modified
Eagle medium alpha (Gibco) supplemented with 10% fetal calf
serum (LabForce AG). Stable cell lines were cultured with the
relevant antibiotics present.
RT-PCR analysis, Western blotting, cell fractionation,
EndoH digests, transient transfections and
immunofluorescence
Total RNA was isolated (GenElute Total RNA kit, Sigma), and
mRNA from 1 mg total RNA was reverse transcribed (Enhanced
avian reverse transcriptase kit, Sigma). PCR reactions were
performed with the equivalent of 200 ng total RNA using primers
specific for ERp90 (for: cagaaattgcccttttggaa; rev: accagtggtaagcc-
cagttg) and actin (for: ggacttcgagcaagagatgg; rev: agcactgtgttggcg-
tacag) and analyzed on 1% agarose gels. To investigate the identity
of the 39 region of the ERp90 mRNA, a PCR was performed using
primers localized to the 39 region of the last exon of the ERp90
mRNA and the 59 region of the 39 untranslated region of the
ERp90 mRNA (for: cgaaagcttacctcc, rev: cgaaagctttttgcc). The
PCR product was gel purified and sequenced. All other methods
were performed as described previously [15].
AMS modification of myc-ERp90 in HEK293-TREX cells
The experiment was performed as described in [17]. Cells were
washed once with ice cold 20 mM NEM in PBS, incubated for
20 min in the same buffer and subsequently lysed in SDS-
containing AMS modification buffer (0.05 M Tris-HCl, 2% SDS,
0.04% (w/v) bromocresol purple, pH 6.8). The cell lysate was then
incubated at 95uC for 5–10 min and either analyzed directly or
treated with TCEP at 25uC for 15 min. AMS was added to a final
concentration of 20 mM, and incubated in the dark for 1 h at
25uC followed by the addition of Laemmli sample buffer. Samples
were analyzed by SDS-PAGE and Western blot.
E. coli expression, purification and AMS modification of
recombinant ERp90 Trx3
A fusion protein of Maltose Binding Protein (MBP, positioned
N-terminally) and the Trx3 domain of ERp90 (positioned C-
terminally) connected with a Factor Xa (FXa) cleavage site was
expressed in the SHuffle T7 Express strain of E. coli (New England
Biolabs, MA, USA). SHuffle cells pre-transformed with a plasmid
for Erv1 and DsbC expression regulated by an arabinose-inducible
promotor (pFH255; kindly provided by Dr. Lloyd Ruddock,
University of Oulu) were transformed with pMAL-c2X/MBP-Xa-
ERp90 Trx3. LB broth containing 100 mg/ml ampicilin and
34 mg/ml chloramphenicol was inoculated with a single colony
and grown overnight at 37uC. This culture was diluted to OD600
0.05 and grown at 37uC. At OD600 ,0.3, the incubation
temperature was changed to 16uC. At OD600,0.4, pre-expression
of Erv1 and DsbC was induced by the addition of 0.5% w/v
arabinose, and 40 min later, 0.5 mM IPTG was added to induce
expression of ERp90 Trx3. Cells were grown overnight, pelleted,
and resuspended in lysis buffer (20 mM Tris-HCl, 200 mM NaCl,
1 mM EDTA, 0.1% Triton X-100 (v/v), 100 mM phenylmethyl-
sulfonyl fluoride, complete EDTA-free protease inhibitor tablet
(Roche, Switzerland), pH 7.4). After sonication, the lysate was
cleared by centrifugation at 14,500 g for 30 min at 4uC. The
cleared lysate was loaded at RT onto an amylose resin (New
England Biolabs, MA, USA) gravity-flow column pre-equilibrated
with column buffer (20 mM Tris-HCl, 200 mM NaCl, pH 7.4).
The column was extensively washed with column buffer and
eluted in the same buffer containing 10 mM maltose. Pooled
elution fractions were incubated in 10 mM NEM at 4uC for 1 h to
block free thiols and dialyzed against FXa buffer (20 mM Tris-
HCl, 50 mM NaCl, 1 mM CaCl2, pH 7.4). The MPB-ERp90
Trx3 fusion protein was cleaved with 3.5 U FXa (Qiagen,
Germany) per mg protein for 12 h at RT. FXa was inactivated
by the addition of 200 mM phenylmethylsulfonyl fluoride, and the
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cleaved protein was dialyzed against low salt buffer (20 mM Tris-
HCl, 20 mM NaCl, pH 8.5) before loading it onto a 1 ml Mono
Q HR 5/5 anion-exchange column (GE Healthcare, UK)
mounted on an A¨KTAexplorer. Subsequent to washing in low
salt buffer, proteins were eluted with a linear gradient developed
over 40 min at 1 ml/min into high salt buffer (20 mM Tris-HCl,
0.5 M NaCl, pH 8.5). The correct molecular mass of ERp90 Trx3
was verified by matrix-assisted laser desorption/ionization mass
spectrometry (expected: 13039 Da; experimentally determined:
13036 Da). The purified protein was used for gel shift assays after
alkylation with AMS. Aliquots of ERp90 Trx3 in 20 mM Tris-
HCl, 1 M NaCl, pH 8.5 were incubated under native or
denaturing conditions (2% SDS), and treated with 10 mM DTT
at 95uC (SDS-containing sample) or room temperature (RT) (all
other samples) for 5 min. Thiol-disulfide exchange reactions were
quenched and proteins were precipitated with 10% TCA followed
by the addition of 0.1% deoxycholate. Samples were incubated on
ice for 30 min, centrifuged 15 min at 4uC at 16,100 g and the
supernatant was removed. The pellet was resolubilized and
denatured in 0.5 M Tris-HCl, 2% SDS, 0.04% (w/v) bromocresol
purple, pH 7.0 and incubated at 95uC for 2 min. Following the
addition of 15 mM AMS, the samples were titrated with 1.5 M
Tris-HCl, pH 8.8 until the color changed from yellow to purple
(bromocresol purple changes color between pH 5.2–6.8), and
incubated in the dark for 1 h at RT followed by the addition of
Laemmli sample buffer. Samples were analyzed on Coomassie-
stained 18% Tris-glycine SDS-PAGE gels.
Metabolic labeling and immunoprecipitations
Pulse-chase experiments with [35S] Express protein labeling mix
(PerkinElmer) and IP from cell lysates were performed as
described [15]. The following lysis buffer was used for native IP:
50 mM HEPES/NaOH pH 7.2, 50 mM NaCl, 125 mM K-
acetate, 2 mMMgCl2, 1 mM EDTA, 3% glycerol, 1% NP-40. To
enrich endogenous ERp90 we performed sequential native and
denaturing IPs. For the latter we used the following denaturing
lysis buffer: 30 mM Tris/HCl pH 8.1, 100 mM NaCl, 5 mM
EDTA, 1.6% SDS. Before adding antibodies, the buffer was
diluted using 2.5% Triton X-100 to a final composition of 30 mM
Tris/HCl pH 8.1, 100 mM NaCl, 5 mM EDTA, 0.4% SDS,
1.9% Triton X-100.
Supporting Information
Figure S1 Identification of ERp90 as an ERFAD-inter-
acting protein. (A) The protein sequence of full-length human
ERp90. The peptides identified by mass spectrometry are
indicated in bold lettering, and cover a total of 14% of the mature
ERp90 protein sequence.
(EPS)
Figure S2 Sequence alignment between ERp90Trx3-5
and ERp57 abb’. Alignment of human ERp57 abb’ domains
with the three thioredoxin-like domains (Trx3-5) closest to the C-
terminus of human ERp90. The alignment was performed with
Muscle (1). The secondary structure of ERp90 was predicted as
described in the legend for Figure 2. The secondary structure of
ERp57 abb’ domains is based on the structure solved by Dong
and colleagues (2). The domains of ERp57 and ERp90 are
indicated with colored lines and cysteine residues are highlighted
in yellow.
(EPS)
Figure S3 Evolutionary conservation of ERp90. A multiple
sequence alignment of the ERp90 protein was performed with
Muscle (1) using the following database entries:Homo sapiens (accession
number Q9P2K2.4), Pan troglodytes (accession number XP_00115
8742.1), Macaca mulatta (accession number XP_001103706.1), Canis
familiaris (accession number XP_537446.2), Bos taurus (accession
number XP_616195.4), Mus musculus (accession number BAD324
31.1), Rattus norvegicus (accession number XP_001072487.1), Gallus
gallus (accession number XP_421472.2), Taeniopygia guttata (accession
number XP_002200455.1), Xenopus tropicalis (accession number
NP_001072460.1), Danio rerio (accession number XP_685017.2),
Branchiostoma floridae (accession number XP_002612374.1), Saccoglossus
kowalevskii (accession number XP_002741184.1), Strongylocentrotus
purpuratus (residue number 468–1288; accession number XP_
001190577.1), and Ciona intestinalis (Ensembl Peptide ID EN-
SCINP00000018039). Black boxes indicate amino acid identities,
and gray boxes show amino acid similarities when found in at least 8
of the 15 sequences. Cysteine residues are shown in yellow. The
predicted signal sequence, N-glycosylation sites (*) and the thior-
edoxin-like domains of human ERp90 are depicted.
(PDF)
Figure S4 Specificity of the antibody against ERp90.
Test of anti-ERp90 on cell lines overexpressing myc-ERp90. Cells
stably expressing myc-ERp90 were [35S] pulse-labeled for
16 hours, Triton X-100 lysates immunoprecipitated either with
anti-myc (lanes 1 and 2) or by the IP-reIP approach with anti-
ERp90 (lane 3), and samples separated by reducing SDS-PAGE.
Part of the eluate was deglycosylated by treatment with PNGaseF.
The position of myc-ERp90 is indicated. CHO, N-glycans.
(EPS)
Text S1 An overview of the cloning work performed to
construct the pcDNA5FRT/myc-ERp90, pcDNA3.hygro/
myc-ERp90, and pMAL-c2X/MBP-Xa-ERp90Trx3 plas-
mids.
(DOC)
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